adverum biotechnologies inc. - ADVM
ADVM
Close Chg Chg %
4.26 0.10 2.35%
Open Market
4.36
+0.10 (2.35%)
Volume: 1.02M
Last Updated:
Dec 8, 2025, 4:00 PM EDT
Company Overview: adverum biotechnologies inc. - ADVM
ADVM Key Data
| Open $4.24 | Day Range 4.23 - 4.38 |
| 52 Week Range 1.78 - 6.12 | Market Cap $96.26M |
| Shares Outstanding 22.08M | Public Float 16.46M |
| Beta 0.87 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$8.57 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 515.17K |
ADVM Performance
No Data Available
ADVM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
2
Full Ratings ➔
About adverum biotechnologies inc. - ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
ADVM At a Glance
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City, California 94063
| Phone | 1-650-656-9323 | Revenue | 1.00M | |
| Industry | Pharmaceuticals: Major | Net Income | -130,927,000.00 | |
| Sector | Health Technology | Employees | 155 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ADVM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 92.382 |
| Price to Book Ratio | 1.377 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.391 |
| Enterprise Value to Sales | 58.396 |
| Total Debt to Enterprise Value | 1.57 |
ADVM Efficiency
| Revenue/Employee | 6,451.613 |
| Income Per Employee | -844,690.323 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.006 |
ADVM Liquidity
| Current Ratio | 5.734 |
| Quick Ratio | 5.734 |
| Cash Ratio | 5.489 |
ADVM Profitability
| Gross Margin | -265.30 |
| Operating Margin | -15,315.90 |
| Pretax Margin | -13,092.70 |
| Net Margin | -13,092.70 |
| Return on Assets | -74.211 |
| Return on Equity | -169.833 |
| Return on Total Capital | -80.611 |
| Return on Invested Capital | -85.897 |
ADVM Capital Structure
| Total Debt to Total Equity | 129.684 |
| Total Debt to Total Capital | 56.462 |
| Total Debt to Total Assets | 50.992 |
| Long-Term Debt to Equity | 121.669 |
| Long-Term Debt to Total Capital | 52.972 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Adverum Biotechnologies Inc. - ADVM
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 7.50M | 3.60M | 1.00M | |
Sales Growth
| - | - | -100.00% | -72.22% | - |
Cost of Goods Sold (COGS) incl D&A
| 4.64M | 6.53M | 5.64M | 3.65M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.64M | 6.53M | 5.64M | 3.65M | |
Depreciation
| 4.64M | 6.53M | 5.64M | 3.65M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +11.71% | +40.54% | -13.54% | -35.28% | |
Gross Income
| 2.85M | (6.53M) | (2.04M) | (2.65M) | |
Gross Income Growth
| +168.66% | -328.65% | +68.69% | -29.79% | |
Gross Profit Margin
| - | +38.07% | -56.78% | -265.30% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 147.91M | 148.48M | 121.75M | 150.51M | |
Research & Development
| 89.18M | 99.28M | 77.48M | 77.04M | |
Other SG&A
| 58.73M | 49.21M | 44.27M | 73.47M | |
SGA Growth
| +29.99% | +0.38% | -18.01% | +23.62% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 1.06M | 2.12M | 200.00K | |
EBIT after Unusual Expense
| (146.12M) | (157.13M) | (123.99M) | (153.16M) | |
Non Operating Income/Expense
| 582.00K | 2.67M | 5.75M | 22.23M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (145.54M) | (154.46M) | (118.24M) | (130.93M) | |
Pretax Income Growth
| -25.04% | -6.13% | +23.45% | -10.73% | |
Pretax Margin
| - | -1,940.53% | -3,284.53% | -13,092.70% | |
Income Tax
| - | - | 74.00K | (1.08M) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | 74.00K | (1.08M) | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (145.54M) | (154.54M) | (117.17M) | (130.93M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (145.54M) | (154.54M) | (117.17M) | (130.93M) | |
Net Income Growth
| -23.86% | -6.18% | +24.18% | -11.75% | |
Net Margin Growth
| - | -1,940.53% | -3,254.58% | -13,092.70% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (145.54M) | (154.54M) | (117.17M) | (130.93M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (145.54M) | (154.54M) | (117.17M) | (130.93M) | |
EPS (Basic)
| -14.8451 | -15.5702 | -11.6207 | -6.6185 | |
EPS (Basic) Growth
| -7.57% | -4.88% | +25.37% | +43.05% | |
Basic Shares Outstanding
| 9.80M | 9.93M | 10.08M | 19.78M | |
EPS (Diluted)
| -14.8451 | -15.5702 | -11.6207 | -6.6185 | |
EPS (Diluted) Growth
| -7.57% | -4.88% | +25.37% | +43.05% | |
Diluted Shares Outstanding
| 9.80M | 9.93M | 10.08M | 19.78M | |
EBITDA
| (140.41M) | (148.48M) | (118.15M) | (149.51M) | |
EBITDA Growth
| -23.40% | -5.75% | +20.43% | -26.54% | |
EBITDA Margin
| - | -1,872.19% | -3,281.86% | -14,950.60% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 4.667 | |
| Number of Ratings | 2 | Current Quarters Estimate | -1.63 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -7.75 | |
| Last Quarter’s Earnings | -1.55 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -6.62 | Next Fiscal Year Estimate | -5.245 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 1 | 2 | 2 |
| Mean Estimate | -1.63 | -1.98 | -7.75 | -5.25 |
| High Estimates | -1.12 | -1.98 | -6.77 | -2.24 |
| Low Estimate | -2.14 | -1.98 | -8.73 | -8.25 |
| Coefficient of Variance | -44.25 | N/A | -17.88 | -81.02 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 2 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 4 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Overweight | Buy |
SEC Filings for Adverum Biotechnologies Inc. - ADVM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Adverum Biotechnologies Inc. - ADVM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 28, 2025 | Braden Michael Leonard | 125,207 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.04 per share | 631,043.28 |
| Mar 28, 2025 | Braden Michael Leonard | 141,800 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.19 per share | 735,942.00 |
| Mar 21, 2025 | BML Capital Management LLC | 2,622,820 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.6 per share | 12,064,972.00 |
| Mar 21, 2025 | BML Capital Management LLC | 2,667,161 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.73 per share | 12,615,671.53 |
| Mar 21, 2025 | BML Capital Management LLC | 2,692,161 | Open market or private purchase of non-derivative security Non-derivative transaction at $4.94 per share | 13,299,275.34 |
| Mar 21, 2025 | BML Capital Management LLC | 2,722,761 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.61 per share | 15,274,689.21 |
| Feb 28, 2025 | Linda M. Rubinstein CHIEF FINANCIAL OFFICER | 19,325 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Linda M. Rubinstein CHIEF FINANCIAL OFFICER | 48,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR; Director | 96,614 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR; Director | 150,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Rabia Gurses Ozden Chief Medical Officer | 8,125 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Rabia Gurses Ozden Chief Medical Officer | 48,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | 42,114 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | 78,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Star Seyedkazemi CHIEF DEVELOPMENT OFFICER | 14,692 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Star Seyedkazemi CHIEF DEVELOPMENT OFFICER | 48,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |